1st Humira biosimilar enters market with two prices

Six years after regulators approved Amjevita, a biosimilar to the nation's most lucrative drug, Humira, Amgen's drug jumped on the U.S. market Jan. 31 with two list prices.

The biosimilar to AbbVie's most profitable drug will either cost 5 percent or 55 percent less than Humira's price, according to Amgen. Humira costs $6,922 for a month's supply, meaning Amjevita's price — depending on the buyer — will be $6,576 or $3,115. The higher price is designed to entice pharmacy benefit managers, and the lower one is for payers, according to Bloomberg

As Humira's 20-year, $114 billion, 247-patent-strong monopoly ends with the first biosimilar, more copycat versions are set to premiere in the next few months.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars

>